The introduction of proteasome inhibitors (PIs), like bortezomib, carfilzomib and ixazomib, into the treatment of multiple myeloma (MM) patients has significantly extended their survival.1 The anti-MM effects of PIs arise mainly through the induction of an apoptotic endoplasmic reticulum stress response in MM cells, although other mechanisms also contribute, including modulation of NF-κB transcription factor signalling and changes to the bone marrow (BM) microenvironment.1 MM, however,...